Fig. 3
Suppression of SIRT6 synergizes doxorubicin-mediated inhibition of proliferation of osteosarcoma cells. a U2OS and KHOS/NP osteosarcoma cells were transfected with control shRNA, shRNA for SIRT6, empty vector, or wild-type SIRT6 and treated with the indicated dose of doxorubicin (0, 0.05, 0.1, 0.2, 0.4, or 0.8 µM) for 24 hours, and then measured with a BrdU proliferation assay. b The U2OS and KHOS/NP cells transfected with control shRNA, shRNA for SIRT6, empty vector, or wild type-SIRT6 were treated with 0.1 µM doxorubicin and measured after 24, 48, and 72 hours for proliferation with a BrdU assay. c A colony-forming assay was performed by seeding U2OS cells (2 × 103) and KHOS/NP cells (2 × 103) transfected with control shRNA, shRNA for SIRT6, empty vector, or wild type-SIRT6, and treating DMSO or 0.1 µM doxorubicin in 24-well culture plates. *; P < 0.05, **; P < 0.001